Are there, or shall we discover, biomarkers to guide PD-1 inhibition? - Wikidata - awgldk - TriplyDB

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

http://www.wikidata.org/entity/Q38838639

about

Part I: Checkpoint inhibitors in cancer therapy.

P2860

Q45958620-1802951E-0709-4A96-A155-DB54A1DBE93E

P2860

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

http://www.wikidata.org/entity/Q38838639

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

@en

type

label

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

@en

prefLabel

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

@en

P1433

Q38838639-E24E1DE9-946A-4359-B2F7-1C1637DFAC96

P1476

Q38838639-AAE62D9D-3C0A-4AE3-B967-B28AA2F4FCE0

P2093

Q38838639-ABF6C69B-F0FC-42A0-938B-5FE37B92C4B2

P2860

Q38838639-157DE650-3D85-4D24-8FED-C39E0D40635A

Q38838639-18D4866F-A796-4BD2-94D2-04DF6E94EAB1

Q38838639-195FE733-4A86-45BC-88A5-0CF3631BA39F

Q38838639-1F64A88C-9396-4C14-96D1-0CC1C4520409

Q38838639-2B42DE3E-C355-4C34-BC68-18D26431CCC7

Q38838639-39D25BCC-AF39-44FD-9405-92431CEDA50F

Q38838639-3A48DDCA-3F2D-4FE1-A168-19775EFED845

Q38838639-4D319098-A98B-4EB0-9915-9C588AC5D5E3

Q38838639-56A49D5D-C764-4BC0-B706-2DAAEBBD824C

Q38838639-5C20264F-3C29-49F2-BB0A-4D26D43CC289

P304

Q38838639-5A1A85F7-80A4-42BC-AE12-22CFE45E6D95

P31

Q38838639-BBC649E2-B0F4-4723-BE0F-FFD797293E0B

Q38838639-ef6279b8-6aaa-4ffc-80fa-fbac323b1046

P356

Q38838639-DDFC177B-4241-4F02-B2F1-A36CCFCBBC2B

P433

Q38838639-361286CF-3434-4ABF-B300-DE44BF7AD7D0

P478

Q38838639-E9C0959B-0AD5-4820-97E7-FFD9F90E7C5E

P50

Q38838639-A48F9A13-9393-42AA-AC2C-413E3BD04B9F

P577

Q38838639-4279B40F-25DD-4C1E-8160-DEE49009748D

P698

Q38838639-86ED499E-4DF4-45CC-8193-71B4C2486B14

P921

Q38838639-EF4ED8BF-124C-4CC3-A321-163E414ABCE9

P356

P1433

P1476

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

@en

P2093

Ramon Andrade de Mello

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Signatures of mutational processes in human cancer

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Genetic basis for clinical response to CTLA-4 blockade in melanoma

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

How tolerogenic dendritic cells induce regulatory T cells

P304

681-686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2016-5000

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Antonio Ascierto

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27197537

http://www.w3.org/2001/XMLSchema#string

P921